Boysen Bio ApS: Financial statements 2020
CVR: 38655590
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
Boysen Bio ApS (CVR 38655590) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -4,270 and a net result of DKK -3,598 compared with DKK -17,696 the year before. Equity in the 2020 report amounted to DKK 25,378. The solvency ratio was 2.7%.
- Gross Profit
- DKK -4,270
- Profit/Loss
- DKK -3,598
- Equity
- DKK 25,378
- Total Assets
- DKK 941,518
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -4 t. | -4 t. | 25 t. | - |
| 2019 | - | -9 t. | -18 t. | 29 t. | - |
Official annual report
How creditworthy is Boysen Bio ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Boysen Bio ApS
Boysen Bio ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named Boysen Bio IVS and GlyProVac IVS. The management consists of Anders Boysen. The company is owned by Anders Boysen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,142 and a net result of DKK -4,142 compared with DKK -4,968 the year before. Equity in the 2025 report amounted to DKK 42,055.